IN BRIEF: Arecor Therapeutics shares rise 8% on AIM debut

Arecor Therapeutics PLC - Saffron Walden, England-based biopharmaceutical - Raises GBP20.0 ...

Alliance News 3 June, 2021 | 12:48PM
Email Form Facebook Twitter LinkedIn RSS

Arecor Therapeutics PLC - Saffron Walden, England-based biopharmaceutical - Raises GBP20.0 million gross in initial public offering on AIM in London. Panmure Gordon places 8.8 million Arecor shares at 226 pence, giving the company a GBP62.5 million market capitalisation on admission. Arecor aims to improve patient care by enhancing existing therapeutic products. Its current focus of internal proprietary product development can be divided into two product classes: diabetes and specialty hospital care. "The group's strategy is to develop an internal portfolio of enhanced proprietary products to a defined value inflexion point prior to partnering with major pharmaceutical and biotechnology companies under a revenue-generating licence model with the potential for the group to receive royalties and significant milestone payments," it said last week in announcing its listing plans.

Current stock price: 244p, up 8.0% from IPO price

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Arecor Therapeutics PLC Ordinary Shares 38.00 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures